Studies have shown that in human malignant tumors, the incidence of RAS protein mutations is quite high, especially in ovarian cancer; the mutation status of KRAS codons 12, 13, and 61 ranges from 6 to 65% in different histo-types [41,42]. The gene discussed is KRAS; the disease is cancer.